利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.026 秒)

    Pyridopyrimidinone antianginal agents
    1.
    发明授权
    Pyridopyrimidinone antianginal agents 失效
    吡啶并嘧啶酮抗心绞痛药

    公开(公告)号：US5591742A

    公开(公告)日：1997-01-07

    申请号：US379531

    申请日：1995-01-31

    申请人： Andrew S. Bell ,  Nicholas K. Terrett

    发明人： Andrew S. Bell ,  Nicholas K. Terrett

    IPC分类号： A61K31/505 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P43/00 ,  C07D471/04 ,  A61K31/535 ,  A61K31/435 ,  C07D413/14 ,  C07D487/02

    CPC分类号： C07D471/04

    摘要： Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein R.sup.1 is H, C.sub.1 -C.sub.4 alkyl CN or CONR.sup.4 R.sup.5 ; R.sup.2 is C.sub.2 -C.sub.4 alkyl; R.sup.3 is SO.sub.2 NR.sup.6 R.sup.7, NO.sub.2, NH.sub.2, NHCOR.sup.8 NHSO.sub.2 R.sup.8 or N(SO.sub.2 R.sup.8).sub.2 ; R.sup.4 and R.sup.5 are each independently selected from H and C.sub.1 -C.sub.4 alkyl; R.sup.6 and R.sup.7 are each independently selected from H and C.sub.1 -C.sub.4 alkyl optionally substituted with CO.sub.2 R.sup.9, OH, pyridyl 5-isoxazolin-3-onyl, morpholino or 1-imidazolidin-2-onyl; or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 1-pyrazolyl or 4-(NR.sup.10)-1-piperazinyl group wherein any of said groups may optionally be substituted with one or two substituents selected from C.sub.1 -C.sub.4 alkyl, CO.sub.2 R.sup.9, NH.sub.2 and OH; R.sup.8 is C.sub.1 -C.sub.4 alkyl or pyridyl; R.sup.9 is H or C.sub.1 -C.sub.4 alkyl; and R.sup.10 is H, C.sub.1 -C.sub.4 alkyl or (hydroxy) C.sub.2 -C.sub.3 alkyl; are selected cGMP PDE inhibitors useful in the treatment of, inter alia, cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

    摘要翻译： PCT No.PCT / EP93 / 02097 371日期1995年1月31日 102（e）日期1995年1月31日PCT提交1993年8月4日PCT公布。 公开号WO94 / 05661 日期：1994年3月17日化学式＆lt; IMAGE＆gt;及其药学上可接受的盐，其中R 1是H，C 1 -C 4烷基CN或CONR 4 R 5; R2是C2-C4烷基; R3是SO2NR6R7，NO2，NH2，NHCOR8 NHSO2R8或N（SO2R8）2; R 4和R 5各自独立地选自H和C 1 -C 4烷基; R 6和R 7各自独立地选自H和任选被CO 2 R 9，OH，吡啶基-5-异恶唑啉-3-基，吗啉代或1-咪唑烷-2-基基取代的C 1 -C 4烷基; 或与它们所连接的氮原子一起形成吡咯烷子基，哌啶子基，吗啉代，1-吡唑基或4-（NR10）-1-哌嗪基，其中任何所述基团可任选被一个或两个选自C 1 -C4烷基，CO 2 R 9，NH 2和OH; R8是C1-C4烷基或吡啶基; R 9为H或C 1 -C 4烷基; R 10为H，C 1 -C 4烷基或（羟基）C 2 -C 3烷基; 被选择用于治疗尤其是心血管疾病如心绞痛，高血压，心力衰竭和动脉粥样硬化的cGMP PDE抑制剂。

    Pyrazolopyrimidinone antianginal agents
    2.
    发明授权
    Pyrazolopyrimidinone antianginal agents 失效
    吡唑嘧啶酮抗心绞痛药

    公开(公告)号：US5346901A

    公开(公告)日：1994-09-13

    申请号：US84827

    申请日：1993-06-29

    申请人： Andrew S. Bell ,  David Brown ,  Nicholas K. Terrett

    发明人： Andrew S. Bell ,  David Brown ,  Nicholas K. Terrett

    IPC分类号： C07D487/04 ,  A61K31/505

    CPC分类号： C07D487/04

    摘要： Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalky)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 -C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

    摘要翻译： 下式的化合物：其中R 1是H，C 1 -C 3烷基，C 3 -C 5环烷基或C 1 -C 3全氟烷基; R2是H，任选被OH，C1-C3烷氧基或C3-C6环烷基取代的C1-C6烷基，或C1-C3全氟烷基; R3是C1-C6烷基，C3-C6炔基，C3-C6炔基，C3-C7环烷基，C1-C6全氟烷基或（C3-C6环烷基）C1-C6烷基; R4与其所连接的氮原子一起形成吡咯烷基，哌啶子基，吗啉代或4-N-（R6） - 哌嗪基; R5是H，C1-C4烷基，C1-C3烷氧基，NR7R8或CONR7R8; R6是H，C1-C6烷基，（C1-C3烷氧基）C2-C6烷基，羟基C2-C6烷基，（R7R8N）C2-C6烷基，（R7R8NCO）C1-C6烷基，CONR7R8，CSNR7R8或C（NH） NR7R8; R 7和R 8各自独立地为H，C 1 -C 4烷基，（C 1 -C 3烷氧基）C 2 -C 4烷基或羟基C 2 -C 4烷基; 及其药学上可接受的盐是用于治疗心血管疾病如心绞痛，高血压，心力衰竭和动脉粥样硬化的选择性cGMP PDE抑制剂。

    Pyrazolopyrimidinone antianginal agents
    3.
    发明授权
    Pyrazolopyrimidinone antianginal agents 失效
    吡唑嘧啶酮抗心绞痛药

    公开(公告)号：US5250534A

    公开(公告)日：1993-10-05

    申请号：US882988

    申请日：1992-05-14

    申请人： Andrew S. Bell ,  David Brown ,  Nicholas K. Terrett

    发明人： Andrew S. Bell ,  David Brown ,  Nicholas K. Terrett

    IPC分类号： C07D487/04 ,  A61K31/505

    CPC分类号： C07D487/04

    摘要： Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 - C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

    摘要翻译： 下式的化合物：其中R 1是H，C 1 -C 3烷基，C 3 -C 5环烷基或C 1 -C 3全氟烷基; R2是H，任选被OH，C1-C3烷氧基或C3-C6环烷基取代的C1-C6烷基，或C1-C3全氟烷基; R3是C1-C6烷基，C3-C6烯基，C3-C6炔基，C3-C7环烷基，C1-C6全氟烷基或（C3-C6环烷基）C1-C6烷基; R4与其所连接的氮原子一起形成吡咯烷基，哌啶子基，吗啉代或4-N-（R6） - 哌嗪基; R5是H，C1-C4烷基，C1-C3烷氧基，NR7R8或CONR7R8; R6是H，C1-C6烷基，（C1-C3烷氧基）C2-C6烷基，羟基C2-C6烷基，（R7R8N）C2-C6烷基，（R7R8NCO）C1-C6烷基，CONR7R8，CSNR7R8或C（NH） NR7R8; R 7和R 8各自独立地为H，C 1 -C 4烷基，（C 1 -C 3烷氧基）C 2 -C 4烷基或羟基C 2 -C 4烷基; 及其药学上可接受的盐是用于治疗心血管疾病如心绞痛，高血压，心力衰竭和动脉粥样硬化的选择性cGMP PDE抑制剂。

    Moment connection for concrete container wall and footing
    6.
    发明授权
    Moment connection for concrete container wall and footing 有权
    混凝土容器墙壁和基础的时间连接

    公开(公告)号：US08336263B2

    公开(公告)日：2012-12-25

    申请号：US12912097

    申请日：2010-10-26

    申请人： Gary R. Schultz ,  Andrew S. Bell

    发明人： Gary R. Schultz ,  Andrew S. Bell

    IPC分类号： E02D27/00

    CPC分类号： E04H4/0093 ,  E04H4/0087 ,  E04H4/1227 ,  E04H2004/146

    摘要： A concrete container including a concrete footing including a shear key; a concrete wall inserted in the shear key; a plurality of footing reinforcing members inserted in the concrete footing on a support side of the shear key and extending above the concrete footing; a plurality of wall reinforcing members inserted in the concrete wall on a support side of the concrete wall and extending diagonally towards the concrete footing; a poured concrete moment connection substantially covering the plurality of footing reinforcing members extending from the pre-cast concrete footing and the plurality of wall reinforcing members extending from the wall.

    摘要翻译： 包括具有剪切键的混凝土基础的混凝土容器; 将混凝土墙插入剪切钥匙; 多个基础加强构件，其在所述混凝土基座中插入所述剪切键的支撑侧并在所述混凝土基础之上延伸; 多个壁加强构件，其插入在混凝土壁的支撑侧上的混凝土壁中并对角地朝向混凝土基部延伸; 倾倒的混凝土力矩连接件基本上覆盖从预铸混凝土基脚延伸的多个基础加强构件和从壁延伸的多个壁加强构件。

    MOMENT CONNECTION FOR CONCRETE CONTAINER WALL AND FOOTING
    7.
    发明申请
    MOMENT CONNECTION FOR CONCRETE CONTAINER WALL AND FOOTING 有权
    混凝土容器墙壁和接头的连接

    公开(公告)号：US20120096634A1

    公开(公告)日：2012-04-26

    申请号：US12912097

    申请日：2010-10-26

    申请人： Gary R. Schultz ,  Andrew S. Bell

    发明人： Gary R. Schultz ,  Andrew S. Bell

    IPC分类号： E04H4/00 ,  E04B1/682 ,  E04B1/04

    CPC分类号： E04H4/0093 ,  E04H4/0087 ,  E04H4/1227 ,  E04H2004/146

    摘要： A concrete container including a concrete footing including a shear key; a concrete wall inserted in the shear key; a plurality of footing reinforcing members inserted in the concrete footing on a support side of the shear key and extending above the concrete footing; a plurality of wall reinforcing members inserted in the concrete wall on a support side of the concrete wall and extending diagonally towards the concrete footing; a poured concrete moment connection substantially covering the plurality of footing reinforcing members extending from the pre-cast concrete footing and the plurality of wall reinforcing members extending from the wall.

    摘要翻译： 包括具有剪切键的混凝土基础的混凝土容器; 将混凝土墙插入剪切钥匙; 多个基础加强构件，其在所述混凝土基座中插入所述剪切键的支撑侧并在所述混凝土基础之上延伸; 多个壁加强构件，其插入在混凝土壁的支撑侧上的混凝土壁中并对角地朝向混凝土基部延伸; 倾倒的混凝土力矩连接件基本上覆盖从预铸混凝土基脚延伸的多个基础加强构件和从壁延伸的多个壁加强构件。